-
公开(公告)号：KR101864121B1
公开(公告)日：2018-06-04
申请号：KR1020150141361
申请日：2015-10-08
Applicant: 충남대학교산학협력단
IPC: A61K36/254 , A23L1/30
Abstract: 본발명은섬오갈피잎 추출물을함유하는혈관질환의예방또는치료용조성물에관한것으로서, 상기섬오갈피잎 추출물은혈관내피세포의 eNOS (endothelial nitric oxide synthase)를활성화시키는효과가우수하여, 동맥경화증, 말초혈관폐쇄증, 혈관재협착증, 고혈압, 협심증, 심근경색, 허혈성심장질환, 뇌졸중, 뇌경색, 뇌출혈등과같은각종혈관질환의치료용조성물로용이하게이용될수 있다.
-
公开(公告)号：KR1020150083698A
公开(公告)日：2015-07-20
申请号：KR1020140003553
申请日：2014-01-10
Applicant: 충남대학교산학협력단 , 잎새마을(주)농업회사법인
IPC: A61K31/704 , A61K31/702 , A61K31/70 , A61P9/00
CPC classification number: A61K31/704 , A61K31/70 , A61K31/702
Abstract: 본발명은장생도라지추출물또는이로부터분리된사포닌화합물을함유하는혈관노화억제용조성물에관한것으로서, 상기조성물은시르투인 1(sirtuin 1)의활성을증가시키고, 혈관내피세포의노화를억제하는효과가우수하여, 혈관노화억제용조성물또는혈관노화예방용건강기능식품으로용이하게사용될수 있다.
Abstract translation: 本发明涉及从其分离出的用于抑制血管老化的桔梗提取物或皂苷化合物。 具有抑制血管内皮细胞老化的优异效果的组合物可以增加sirtuin 1的活化，因此可有效地用作抑制血管衰老的组合物或用于预防血管老化的健康功能食品。
-
-
4.发明公开
公开(公告)号：KR1020140112147A
公开(公告)日：2014-09-23
申请号：KR1020130026058
申请日：2013-03-12
Applicant: 충남대학교산학협력단
IPC: A61K31/05 , A61K31/19 , A61K31/185 , A61P3/04
Abstract: The present invention relates to a composition comprising 3-caffeoyl-4-dihydrocaffeoylquinic acid for preventing or treating fatty liver or obesity. The 3-caffeoyl-4-dihydrocaffeoylquinic acid has an excellent effect of inhibiting the synthesis of fatty acids, cholesterol, and triglycerides in a fatty liver cell model, increases the activity of AMPK which is associated with lipogenesis suppression, and has an excellent effect of inhibiting activities of SREBP-1 and FAS which are transcription factors of fatty acid synthesis, thus can be usefully applied as a therapeutic agent for fatty liver or obesity.
Abstract translation: 本发明涉及包含用于预防或治疗脂肪肝或肥胖症的3-咖啡酰基-4-二氢樟脑醌奎酸的组合物。 3-咖啡酰-4-二氢樟脑醌酸在脂肪肝细胞模型中具有抑制脂肪酸，胆固醇和甘油三酸酯合成的优异效果，增加了与脂肪生成抑制相关的AMPK的活性，并且具有优异的 抑制作为脂肪酸合成转录因子的SREBP-1和FAS的活性，因此可以有效地用作脂肪肝或肥胖的治疗剂。
-
公开(公告)号：KR101323157B1
公开(公告)日：2013-10-30
申请号：KR1020100107610
申请日：2010-11-01
Applicant: 충남대학교산학협력단
IPC: A61K31/19 , A61K31/185 , A61K36/185 , A61P35/00
Abstract: 본 발명은 함초 유래의 3-카페오일-4-다이하이드로카페오일 퀴닉산(3-caffeoyl-4-dihydrocaffeoylquinic acid, CDCQ)을 함유하는 암 전이 억제용 약학 조성물에 관한 것으로, 본 발명의 함초 유래의 3-카페오일-4-다이하이드로카페오일 퀴닉산(3-caffeoyl-4-dihydrocaffeoylquinic acid, CDCQ)을 함유하는 조성물은 세포침투에 관여하는 세포 기저막 용해효소 MMP(matrix metalloprotease)-2 및 MMP-9(matrix metalloprotease-9)의 활성을 저해하고 암세포 전이를 억제시키는 효과가 뛰어나 암세포에 대한 전이를 억제시키는 의약품이나 암 전이 예방용 건강기능식품으로 유용하게 사용될 수 있다.
-
Patent Agency Ranking
公开(公告)号：KR101322664B1
公开(公告)日：2013-10-30
申请号：KR1020130036604
申请日：2013-04-04
Applicant: 충남대학교산학협력단
IPC: A61K31/352 , A61K31/35 , A61P35/00
Abstract: PURPOSE: An anticancer composition comprising mollugin is provided to use as a therapeutic agent for cancer patients who have tolerance to existing anticancer drugs by having an excellent effect of killing multidrug resistance cancer cells. CONSTITUTION: An anticancer composition having an effect of killing multidrug resistance cancel cells comprises mollugin of chemical formula 1. The multidrug resistance cancer cells are cancer cells which express multidrug resistance 1 (MDR1). The composition increases activation of AMP-activated protein kinase (AMPK). An anticancer drung is added to the composition. The mollugin is comprised in the composition in a ratio of 0.001-99 wt%.
Abstract translation: 目的：提供包含蜕皮素的抗癌组合物，作为对现有抗癌药物具有耐受性的癌症患者的治疗剂，具有杀死多药耐药性癌细胞的优异效果。 构成：具有杀伤多药耐药性细胞杀伤作用的抗癌组合物包括化学式1的蜕皮。多药耐药性癌细胞是表达多药耐药性1（MDR1）的癌细胞。 组合物增加AMP活化蛋白激酶（AMPK）的活化。 向组合物中加入抗癌剂。 该组合物以0.001-99重量％的比例包含该组合物。
-
-
公开(公告)号：KR101834550B1
公开(公告)日：2018-03-05
申请号：KR1020150171156
申请日：2015-12-03
Applicant: 충남대학교산학협력단
Abstract: 본발명은 3-카페오일-4-디히드로카페오일퀴닉산을유효성분으로함유하는혈관질환의예방, 개선또는치료용조성물에관한것으로, 본발명에따른함초()로부터분리한 3-카페오일-4-디히드로카페오일퀴닉산(3-caffeoyl-4-dihydrocaffeoylquinic acid)을혈관내피세포에처리하였을때, phospho-eNOS(endothelial nitric oxide synthase)의발현량을증가시켜 NO(nitric acid)의생성량이증가되고, 생성된 NO가혈관으로유리되어평활근(smooth muscle)의이완을유도하여혈관을이완시키므로고혈압, 동맥경화, 관상동맥질환, 뇌혈관질환, 말초혈관질환또는대동맥질환등의혈관질환의예방, 개선또는치료용조성물로유용하게이용될수 있다.
-
公开(公告)号：KR1020170041997A
公开(公告)日：2017-04-18
申请号：KR1020150141361
申请日：2015-10-08
Applicant: 충남대학교산학협력단
IPC: A61K36/254 , A23L1/30
Abstract: 본발명은섬오갈피잎 추출물을함유하는혈관질환의예방또는치료용조성물에관한것으로서, 상기섬오갈피잎 추출물은혈관내피세포의 eNOS (endothelial nitric oxide synthase)를활성화시키는효과가우수하여, 동맥경화증, 말초혈관폐쇄증, 혈관재협착증, 고혈압, 협심증, 심근경색, 허혈성심장질환, 뇌졸중, 뇌경색, 뇌출혈등과같은각종혈관질환의치료용조성물로용이하게이용될수 있다.
Abstract translation: 本发明并涉及一种用于预防或治疗血管疾病，包括岛刺五加叶提取物的组合物的效果，该岛刺五加叶提取物激活的eNOS（内皮型一氧化氮合酶）的血管内皮细胞的固体，动脉硬化， 外周血管梗阻，血管再狭窄，高血压，心绞痛，心肌梗塞，缺血性心脏疾病，中风，脑梗塞，血管疾病的各种治疗组合物，如脑出血，可以容易地使用。
-
公开(公告)号：KR1020160101535A
公开(公告)日：2016-08-25
申请号：KR1020150024297
申请日：2015-02-17
Applicant: 충남대학교산학협력단 , 주식회사 장생도라지
IPC: A61K31/704 , A23L1/30
Abstract: 본발명은도라지사포닌(saponin) 및이로부터분리된플라티콘산 A(platyconic acid A)를유효성분으로함유하는혈관신생(Angiogenesis) 억제용조성물에관한것으로, 구체적으로, 본발명의도라지사포닌및 이로부터분리된플라티콘산 A는혈관신생과관련된세포이동및 튜브형성억제하는활성이우수하고, 혈관내피성장인자로유도된혈관신생을농도의존적으로억제하므로, 혈관신생억제, 및혈관신생이비정상적으로조절되는암전이를포함하는다양한질환의치료제로유용하게사용될수 있다.
Abstract translation: 本发明涉及一种用于抑制血管生成的组合物，其含有作为活性成分从其中分离出的桔梗皂甙和扁桃酸酸A. 详细地说，根据本发明，从其分离出的扁柏皂苷和扁桃酸A具有优异的抑制细胞迁移和血管生成相关管形成的活性，浓度依赖性地抑制血管内皮生长因子诱导的血管生成，从而被用作 用于抑制血管发生的治疗剂和包括血管生成异常调节的癌症转移的各种疾病。
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.019 seconds)
